<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808934</url>
  </required_header>
  <id_info>
    <org_study_id>X9001275</org_study_id>
    <nct_id>NCT04808934</nct_id>
  </id_info>
  <brief_title>NOAC Portuguese Real World Study</brief_title>
  <official_title>Stroke/Systemic Embolism and Major Bleeding in Patients Newly Treated With Oral Anticoagulants: a Real World Study From Portuguese Administrative Claims Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if there is any difference in the effectiveness and safety outcomes of patients&#xD;
      with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>stroke/systemic embolism event</measure>
    <time_frame>between 2014 and 2018</time_frame>
    <description>To compare the risk of stroke (either ischemic or hemorrhagic) or SE among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>major bleeding event</measure>
    <time_frame>between 2014 and 2018</time_frame>
    <description>To compare the risk of major bleeding (gastrointestinal [GI], intracranial [IC] and other) among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versusVKAs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ischemic stroke event</measure>
    <time_frame>between 2014 and 2018</time_frame>
    <description>To compare the risk of ischemic stroke among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemorrhagic stroke event</measure>
    <time_frame>between 2014 and 2018</time_frame>
    <description>To compare the risk of hemorrhagic stroke among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic embolism event</measure>
    <time_frame>2014-2018</time_frame>
    <description>To compare the risk of systemic embolism among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major GI bleeding event</measure>
    <time_frame>2014-2018</time_frame>
    <description>To compare the risk of major GI bleeding among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major IC bleeding event</measure>
    <time_frame>2014-2018</time_frame>
    <description>To compare the risk of major IC bleeding among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>other major bleeding event</measure>
    <time_frame>2014-2018</time_frame>
    <description>To compare the risk of other major bleeding among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Stroke</condition>
  <condition>Systemic Embolism</condition>
  <condition>Major Bleeding</condition>
  <arm_group>
    <arm_group_label>Non-Valvular Atrial Fibrillation (NVAF) Adults</arm_group_label>
    <description>Adult patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban or VKAs between June 16, 2014 and December 31, 2018.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Adults receiving apixaban</description>
    <arm_group_label>Non-Valvular Atrial Fibrillation (NVAF) Adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>Adults receiving dabigatran</description>
    <arm_group_label>Non-Valvular Atrial Fibrillation (NVAF) Adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban</intervention_name>
    <description>Adults receiving rivaroxaban</description>
    <arm_group_label>Non-Valvular Atrial Fibrillation (NVAF) Adults</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKAs</intervention_name>
    <description>Adults receiving VKA</description>
    <arm_group_label>Non-Valvular Atrial Fibrillation (NVAF) Adults</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Not applicable, this is a retrospective study&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients will be selected from the CCF database based on an apixaban, dabigatran,&#xD;
        rivaroxaban or VKAs filled prescription between June 16, 2014 and December 31, 2018.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years on the index date.&#xD;
&#xD;
          -  At least 1 OAC (apixaban, dabigatran, rivaroxaban, VKAs) dispensed during the&#xD;
             identification period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Specialty of the physician responsible for the OAC prescription in the index date is&#xD;
             one of the following: orthopedics, general surgery, vascular surgery or any other&#xD;
             surgical specialty;&#xD;
&#xD;
          -  Duration of OAC therapy during follow-up inferior to the cut-off defined during the&#xD;
             feasibility assessment (except if the patient was admitted to in-hospital care during&#xD;
             follow-up);&#xD;
&#xD;
          -  The OAC dispensed in the index date was one of the following: dabigatran 75 mg or&#xD;
             rivaroxaban 10 mg&#xD;
&#xD;
          -  Hospital claims lacking a diagnosis code indicative of AF during the study period;&#xD;
&#xD;
          -  Hospital claim indicating a diagnosis or procedure code indicative of pregnancy or&#xD;
             childbirth during the study period;&#xD;
&#xD;
          -  Hospital claim indicating a diagnosis or procedure code indicative of valvular heart&#xD;
             disease, venous thromboembolism, cardiac surgery, pericarditis, hyperthyroidism and&#xD;
             thyrotoxicity during the baseline period;&#xD;
&#xD;
          -  Hospital claim indicating a diagnosis or procedure code indicative of hip and knee&#xD;
             replacement surgery during the 6 weeks prior to the index date. Patients with past use&#xD;
             of OAC will be excluded. Therefore, patients meeting any of the following criteria&#xD;
             will be excluded:&#xD;
&#xD;
          -  Had any OAC (apixaban, dabigatran, edoxaban, rivaroxaban, VKAs) dispensed during the&#xD;
             12-month baseline period;&#xD;
&#xD;
          -  Had &gt;1 OAC dispensed on the index date.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

